| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8440633 | European Journal of Cancer | 2017 | 8 Pages |
Abstract
CBZ/prednisone administered weekly to 'unfit' mCRPC patients appears to be as effective as classical standard 3-week scheme (TROPIC study)Â but with significantly lower toxicities and better tolerance. Early CTC response appears to be valuable as an early end-point of therapeutic efficacy.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Miguel Ángel Climent, Begoña Pérez-Valderrama, Begoña Mellado, Eva MarÃa Fernández Parra, Ovidio Fernández Calvo, MarÃa Ochoa de Olza, Laura Muinelo Romay, Urbano Anido, Montserrat Domenech, Susana Hernando Polo, José Ángel Arranz Arija,